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B-Type Natriuretic Peptide: A Predictor for Mortality, 
Intensive Care Unit Length of Stay, and Hospital Length of 
Stay in Patients With Resolving Sepsis
Harsimar Singha, Daryl Ramaib, d, Harshil Patela, Marina Iskandira, Sarina Sachdeva, 
 Rabjot Raib, Jay Patoliab, Getaw Worku Hassenc
Abstract
Background: B-type natriuretic peptide (BNP) is a hormone secreted 
by cardiomyocytes in response to myocardial ischemia, increased 
ventricular wall tension, and overload. BNP is utilized as a diagnostic 
and prognostic marker in congested heart failure (CHF). Its prognos-
tic value in sepsis is unknown. The aim of this study is to determine 
if BNP correlates with increased in-hospital mortality for septic pa-
tients.
Methods: This was a retrospective study of 505 patients admitted 
for sepsis or severe sepsis or septic shock during the period of Janu-
ary 2013 and August 2014. Patients that received > 3 L of intrave-
nous fluids on presentation were included. Intensive care unit length 
of stay (ICULOS), hospital length of stay (HLOS) and in-hospital 
mortality were measured. Mean BNP level was calculated and com-
pared to ICULOS and HLOS and in-hospital mortality. Controlled 
variables included ejection fraction (measured by echocardiogram 
within 6 months of presentation), glomerular filtration rate (calculated 
by Cockroft-Gault equation), patient demographics, and lactic acid 
trends. Exclusion criteria were no echocardiogram within 6 months 
of admission, no BNP levels on admission, and no repeat lactate or 
rising lactate levels within 24 h to indicate worsening sepsis.
Results: Patients’ mean BNP with in-hospital mortality was 908 
pg/mL as compared to mean BNP of 678 pg/mL in survivors. T-test 
comparisons were statistically significant (P = 0.0375). The Kaplan-
Meier curve for BNP as a predictor for in-hospital mortality showed 
that for the first 25 days, patients with BNP higher than 500 pg/mL 
had a higher mortality than patients with BNP lower than 500 pg/mL. 
When comparing HLOS, there is a statistically significant correlation 
(P = 0.0046). A similar scatter plot was prepared for ICULOS which 
showed there was a weak positive correlation (r = 0.199).
Conclusion: Septic patients with in-hospital mortality had an average 
BNP of 908 pg/mL and statistically significant higher HLOS.
Keywords: Brain natriuretic peptide; Diagnostic markers; Sepsis; 
Mortality; Intensive care unit
Introduction
B-type natriuretic peptide (BNP) is a hormone secreted into 
the blood by cardiomyocytes, largely in response to myocar-
dial ischemia, increased ventricular wall tension, and pres-
sure overload [1]. BNP affects salt and water homeostasis, 
protecting the heart from volume overload [2]. Specifically, 
it induces vaso-relaxation, diuresis, and natriuresis [3]. Due 
to these mechanisms, BNP is widely utilized as a diagnostic 
and prognostic marker in congested heart failure (CHF) [4], 
and is regarded as a strong predictor of mortality and adverse 
outcomes in patients with acute coronary syndrome [5], pul-
monary embolism [6], and stable coronary artery disease [7].
BNP and N-terminal pro-BNP (NT-proBNP) have been 
shown to have diagnostic, therapeutic, and prognostic utility in 
patients with normal renal function. Systemic BNP levels can 
be influenced by the degree of renal function, rendering BNP 
and NT-proBNP of limited functionality during renal disease 
[8]. However, it should be noted that these markers remain re-
liable predictors of mortality in dialysis patients, independent 
of dialysis modality and degree of fluid volume control [9].
Sepsis is one of the leading causes of mortality in inten-
sive care units (ICUs) [10]. It occurs when an infection leads 
to widespread immune activation, causing diffuse circula-
tory abnormalities and multiple organ failures [11-13]. It is a 
complex pathophysiological process and shows high immune 
variability in patient populations of different ethnicities and 
gender [14]. Accordingly, several studies have investigated the 
implementation of a combination of various biomarkers and 
APACHE-II/SOFA scores in order to achieve better sensitiv-
ity and specificity where single biomarkers have failed to pro-
duce [15-21]. Factors that attribute to a rise in BNP levels in 
sepsis include pro-inflammatory cytokine over-secretion [22], 
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proceeding systolic and diastolic biventricular abnormalities 
[23], altered BNP clearance [24], renal failure [25], and sepsis-
associated acute lung injury or acute respiratory distress syn-
drome (ARDS) [26].
The aim of this study is to determine whether a high initial 
BNP level predicts higher mortality and morbidity in septic pa-
tients while controlling for ejection fraction (EF), glomerular 
filtration rate (GFR), and fluids administered for resolution of 
sepsis within the first 24 h.
Materials and Methods
Patients were selected based on the Surviving Sepsis Cam-
paign: International Guidelines for Management of Severe 
Sepsis and Septic Shock: 2012. Patients were pooled under 
SIRS criteria, sepsis, severe sepsis or septic shock.
Study population
The study was a retrospective chart review of patients admit-
ted under International Classification of Disease (ICD) code 9 
for sepsis, severe sepsis, and septic shock between the dates 
of January 1, 2013 and August 31, 2014. Patients were diag-
nosed with sepsis by the ED physician during admission or 
were diagnosed by the admitting physician in the ED or medi-
cal floors. The amount of fluid administered was calculated for 
the first 24 h after the diagnosis of sepsis. The fluid values 
included the amount of fluid administered within antibiotics, 
bolus and maintenance intravenous (IV) fluids, and any other 
IV medications. Patients that received more than 3 L of fluid 
within 24 h after being diagnosed with sepsis were included in 
our study. The value of 3 L fluids was established based on the 
30 cc/kg model for fluid resuscitation in sepsis as this would 
account for most patients. To ensure that sepsis was resolving, 
we included lactate trends of within 24 h and a final lactate. All 
505 patients included in the study had decreasing lactate with-
in 24 h. Patients with rising lactate levels indicating worsening 
sepsis were excluded from this study. EF was also recorded for 
patients in the last 6 months of presentation or during their ad-
mission. Low EF was defined as less than 45% and normal EF 
was defined as more than or equal to 45%. GFR was calculated 
by Cockroft-Gault equation based on the initial creatinine and 
BUN along with weight on presentation [27]. The normal BNP 
based on our laboratory standards ranged from 2 to 100 pg/mL. 
Patients were excluded if there was no recent echocardiogram 
within 6 months, no BNP drawn on admission, or signs indi-
cating worsening sepsis, i.e. no repeat lactate level or rising 
lactate levels.
Statistical analysis
Patients’ ICU length of stay (ICULOS), hospital length of stay 
(HLOS), and in-hospital mortality were recorded. BNP was 
measured in 505 patients. Eighteen patients were excluded be-
cause of incomplete data, leaving a final study population of 
487 patients. One hundred and ninety-four patients had BNP 
concentrations > 500 pg/mL. The present cohort had fewer 
males (43.5% vs. 56.5%), more signs of congested heart fail-
ure (CHF) (54.2% vs. 45.5%), and 25% in-hospital death (P 
< 0.001). Furthermore, fewer patients had an EF of less than 
45% (21.4% vs. 78.6%; P = 0.246). Data analyses were con-
ducted by comparing in-hospital mortality, HLOS and ICU-
LOS for patients with BNP greater than 500 and less than 500. 
BNP level of less than 100 has a high negative predictive value 
(90%), while the BNP range of 100 - 500 is referred as the 
“gray-zone” and has been debated for being diagnostically 
ambiguous as a marker for assessing clinical outcomes in pa-
tients with CHF [28, 29]. We therefore chose a BNP of 500 as 
our cut-off, and compared the average BNP levels of patients 
with mortality versus patients who survived. We calculated the 
relative risk (RR) of in-hospital death for patients with high 
BNP (> 500) compared to low BNP (≤ 500) using robust Pois-
son regression model, and calculated Kaplan-Meier curves to 
descriptively explore differences in mortality. On visual analy-
sis of survival curves by low vs. high BNP, the data did not 
meet the proportional hazards assumption, and thus no formal 
Table 1.  Characteristics of Study Demographics
n % In-hospital death P-value
Gender
  F 275 56.5 0.251 0.731
  M 212 43.5 0.269
EF
  < 45% 104 21.4 0.308 0.246
  > 45% 383 78.6 0.245
IVF
  > 3 L 113 31.7 0.372 0.001
  < 3 L 243 68.3 0.198
BNP
  > 500 194 41.5 0.278 0.333
  < 500 273 58.5 0.234
Intubation
  Yes 282 57.8 0.139 < 0.001
  No 206 42.2 0.422
Signs of CHF
  Yes 229 54.21 0.279 < 0.59
  No 191 45.5 0.251
On Lasix
  Yes 254 57.92 0.31 0.025
  No 178 42.08 0.208
In-hospital death
  Yes 126 25.87 < 0.001
  No 361 74.13
EF: ejection fraction; IVF: intravenous fluids; CHF: congestive heart 
failure.
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hypothesis testing was conducted to compare mortality rates. 
Instead, we calculated relative risk for mortality using robust 
Poisson regression. To calculate the ratio of lengths of stay in 
the hospital and in the ICU between patients with high vs. low 
BNP, we used negative binomial regression. All regression 
analyses were adjusted for GFR and EF, as BNP levels can be 
confounded by renal failure and severe heart failure. Results 
were considered statistically significant if two-sided P values 
were less than 0.05. All analyses were conducted using R Sta-
tistics version 3.3.
Results
As an overview, the median BNP level for our selected patient 
population (n = 505; 56% F, 44% M) was 410 pg/mL (Table 
1). Median HLOS and ICULOS were 11 and 3 days, respec-
tively. These patients showed decreasing lactate levels, which 
indicated resolving sepsis (median final lactate 1.8 mmol/L). 
The Kaplan-Meier curve for BNP as a predictor for in-hospital 
mortality showed that for the first 25 days, patients with a BNP 
greater than 500 pg/mL had a higher mortality than patients 
with BNP less than 500 pg/mL (Fig. 1). However, there was no 
statistically significant difference in risk of mortality for pa-
tients with high against low BNP, either before (RR = 1.2, 95% 
confidence interval (CI): 0.9 - 1.6) or after EF and GFR (RR 
= 1.0, 95% CI: 0.7 - 1.5) adjustment. Also, there was no dif-
ference in ICULOS between patients with a higher BNP level 
compared to those with a lower BNP level either before (IRR = 
1.1, 95% CI: 0.9 - 1.5) or after EF and GFR (RR = 1.1, 95% CI: 
0.8 - 1.4) adjustment. For HLOS, before adjusting for EF and 
GFR, patients with a higher BNP stayed 21% longer than those 
with a lower BNP (RR = 1.21, 95% CI: 1.04 - 1.40), which was 
attenuated but still significant after adjusting for EF and GFR 
(RR = 1.18, 95% CI: 1.01 - 1.39, P = 0.042).
Discussion
We evaluated a cohort of patients who received 3 L of fluid re-
suscitation and decreasing lactic acid levels trends. Our study 
demonstrated a Kaplan-Meier trend for BNP and the risk of 
mortality in patients with resolving sepsis. Specifically, BNP 
levels greater than 500 pg/mL were predictive of hospital mor-
tality within the first 25 days. Our study showed that sepsis 
mortality was associated with an average of 300 higher BNP 
units. Additionally, BNP was associated with HLOS. Using 
these findings, we support the use of BNP as a rapid bedside 
tool for risk stratifying septic patients.
While the use of BNP has been well studied in the man-
agement and prognosis of patients with CHF, coronary syn-
dromes, and pulmonary embolism, its role as a prognostic 
marker in septic patients is still debatable. Specifically, its role 
in patients with resolving sepsis has not been assessed prior 
to our analysis. Apparently, a number of reasons can be ac-
counted for an elevated BNP level in septic patients, including 
sepsis-induced biventricular dilatation [30], the stimulation 
of lipopolysaccharide [31], proinflammatory cytokines [8], 
impaired renal clearance [32], volume resuscitation [33], and 
sepsis-associated acute lung injury or ARDS [25].
Several studies have been attempted to establish if BNP or 
its precursor Pro-BNP are significantly associated with an in-
creased risk of mortality. In a meta-analysis involving a total of 
1,865 patients, both inactive and active forms natriuretic pep-
tide were elevated and significantly associated with increased 
risk of mortality, with a sensitivity and specificity of 79% and 
60%, respectively [7]. Another study involving 254 patients 
showed that NT-proBNP was an independent predictor of 
mortality within the first 7 h after admission [34]. In addition, 
Guaricci et al (2015) showed that NT-proBNP changes within 
72 h could predict mortality at 28 days in patients with septic 
shock. The study also found that levels greater than 1,000 pg/
mL at 72 h were associated with an adverse outcome, sensitiv-
ity and specificity of 95.5% and 94.4%, respectively [4]. Our 
study did not investigate the predictive value of the inactive 
forms of BNP.
Serial BNP level might be a useful aide in the early de-
tection, stratification, and management of high-risk septic 
patients. Chen and Li (2009), and Post et al (2008) have dis-
cussed the prognostic value when BNP is used as an adjunct 
to severity scales such as acute physiology and chronic health 
evaluation (APACHE) II and sequential organ failure assess-
ment (SOFA) scores. They report that by combining BNP with 
severity scores, the cumulative result may yield greater prog-
nostic information, and hence facilitate decision making for 
clinicians and families [23, 35]. However, a review of the lit-
erature shows variations in the optimal cut-off point of BNP, 
ranging from 32.1 to 681.4 pg/mL [23, 35-41]. Additionally, 
it is unclear if some of these studies accounted for initial fluid 
resuscitation or sepsis resolution.
Elevated BNP indicates that patients stayed longer in hos-
pital and ICU settings. While there are only a few published 
articles which have investigated this association, our study 
supports these findings. Zhang et al (2012) reported that a 
BNP greater than 100 pg/mL was predictive of ICULOS > 7 
days, and HLOS > 12 days [42]. Zhao et al (2009) also showed 
Figure 1. Kaplan-Meier curve showing BNP plotted over time (days) 
versus survival or mortality. Red: low BNP; blue: high BNP.
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that the ICULOS was significantly higher in the BNP elevated 
cohort compared to the BNP normal group (23.7 ± 7.5 days vs. 
14.9 ± 5.1 days, P < 0.05) [37]. Our study reported that patients 
with a high BNP had 1.18 times longer average hospital stay. 
A potential relationship was observed for ICULOS but was di-
minished after adjusting for EF and GFR. Similarly, while our 
study did not show any statistical significance correlating BNP 
and mortality, the Kaplan-Meier curve does indicate a trend 
which should be evaluated in a larger cohort.
Renal disease and plasma BNP share an inverse relation-
ship. In fact, GFR is inversely related to BNP concentration 
[32]. This effect is also observed for the inactive forms of BNP. 
Therefore, the clinical values of BNP differ in patients with re-
nal insufficiency and those with normal renal function. To our 
best knowledge, there are no clinical guidelines for correcting 
BNP in the setting of renal insufficiency. As a result, the use 
of BNP as a biomarker should be taken within the appropriate 
clinical context.
Conclusion
Our study demonstrates that BNP could be a powerful tool that 
can be used to predict mortality in patients with resolving sep-
sis. We have also shown that BNP level can also aid in deter-
mining HLOS and ICULOS. Thus, the clinical value of BNP 
can facilitate discussions with patient prognosis, decisions re-
garding interventions, and continuity of care. While this test 
is inexpensive, rapid, and widely available, further research 
with larger sample sizes is warranted to clarify the optimal cut-
off point in the context of both renal insufficiency and normal 
functioning kidneys.
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